US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evofem Biosciences, Inc.

0.0100

0.0000

Volume:39.48K

Turnover:390.83

Market Cap:1.13M

PE:-0.30

High:0.0102

Open:0.0102

Low:0.0093

Close:0.0100

Loading ...

Overview Company News Filings

Evofem Biosciences Secures $1.4M Convertible Notes and Warrants Deal with Aditxt

Windtree Contracts Chinese Firm to Make Evofem's Contraceptive

Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch

Evofem Biosciences Unveils Promising Results for SOLOSEC in Treating Recurrent Bacterial Vaginosis at ACOG Meeting

Evofem Biosciences CEO Saundra Pelletier Joins Aditxt Board of Directors to Propel Growth Strategy

IMAC Holdings Inc. Appoints Jason Lobel and Saundra Pelletier to Board of Directors

Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market

Evofem Signs Solosec License Agreement for Middle East With Pharma 1

THOMSON REUTERS

Evofem Biosciences Q1 Sales $845.00K Down From $3.60M YoY

Evofem Biosciences Reports Q1 2025 Net Income of $1M, Reversing $4.9M Loss YoY; EPS at $0.01

Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS

Evofem Biosciences Q1 Net Income USD 956 Thousand

THOMSON REUTERS

Evofem Biosciences Q1 Operating Expenses USD 518 Thousand

THOMSON REUTERS

Evofem Biosciences Expands Agreement with Pharma 1 Drug Store to Include New Product Packaging

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EVFM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVFM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","market":"US","secType":"STK","nameCN":"Evofem Biosciences, Inc.","latestPrice":0.01,"timestamp":1751562000000,"preClose":0.01,"halted":0,"volume":39482,"delay":15,"floatShares":113354642,"shares":113356354,"eps":-0.032965,"marketStatus":"Market Closed","change":0,"latestTime":"07-03 13:00:00 EDT Delay","open":0.0102,"high":0.0102,"low":0.0093,"amount":390.83299000000005,"amplitude":0.09,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.032965,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"exchange":"PINK","adjPreClose":0.01,"volumeRatio":0.22912586688216738},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","floatShares":113354642,"roa":"-26.70%","roe":"-387.27%","lyrEps":-0.119222,"volumeRatio":0.22912586688216738,"shares":113356354,"dividePrice":0,"high":0.0102,"amplitude":0.09,"preClose":0.01,"low":0.0093,"week52Low":0.00605,"pbRate":"-0.02","psRate":"0.07","week52High":0.0155,"institutionHeld":0,"latestPrice":0.01,"eps":-0.032965,"divideRate":0,"volume":39482,"delay":15,"ttmEps":-0.032965,"open":0.0102,"prevYearClose":0.0099,"prevWeekClose":0.0094,"prevMonthClose":0.0098,"prevQuarterClose":0.0098,"fiveDayClose":0.0095,"twentyDayClose":0.0094,"sixtyDayClose":0.0082},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVFM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548817724","title":"Evofem Biosciences Secures $1.4M Convertible Notes and Warrants Deal with Aditxt","url":"https://stock-news.laohu8.com/highlight/detail?id=2548817724","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548817724?lang=en_us&edition=fundamental","pubTime":"2025-07-03 04:14","pubTimestamp":1751487285,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has entered into a securities purchase agreement with Aditxt, Inc., involving the sale and issuance of senior subordinated convertible notes and warrants for common stock. The agreement, which closed on June 26, 2025, includes notes with an original principal amount of $1,423,076.92 and warrants to purchase 92,407,592 shares of common stock. Aditxt paid approximately $650 per $1,000 of the principal amount of the notes and warrants, resulting in net proceeds of about $925,000 for Evofem. The notes, accruing interest at 8% per annum, are convertible at $0.0154 per share and mature on June 26, 2028. The warrants are exercisable immediately at the same price per share and expire five years from issuance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDL9rFYXD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADTX","BK4139","BK4007","BK4584","EVFM"],"gpt_icon":0},{"id":"2546519027","title":"Windtree Contracts Chinese Firm to Make Evofem's Contraceptive","url":"https://stock-news.laohu8.com/highlight/detail?id=2546519027","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546519027?lang=en_us&edition=fundamental","pubTime":"2025-06-27 04:57","pubTimestamp":1750971420,"startTime":"0","endTime":"0","summary":"Windtree Therapeutics said it has contracted with a pharmaceutical manufacturer in China to produce Evofem Biosciences's hormone-free contraceptive product Phexxi at a low cost.The biotechnology company, Evofem's sourcing partner for Phexxi since March, said Thursday that the contract should cut Phexxi's manufacturing costs by over 50% by the end of 2026.Windtree expects to start seeing some revenue from the arrangement next year.Early-stage manufacturing is set to begin later this year.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WINT","BK4007","BK4584","EVFM","BK4139"],"gpt_icon":0},{"id":"2545414620","title":"Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2545414620","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545414620?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:47","pubTimestamp":1750682845,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates  Ministry of Health and Prevention seeking approval to commercialize PHEXXI, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL8d30mD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","EVFM","BK4007"],"gpt_icon":0},{"id":"2542581779","title":"Evofem Biosciences Unveils Promising Results for SOLOSEC in Treating Recurrent Bacterial Vaginosis at ACOG Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542581779","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542581779?lang=en_us&edition=fundamental","pubTime":"2025-06-11 20:14","pubTimestamp":1749644059,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has announced notable findings from a clinical study on SOLOSEC  2 g oral granules, targeting recurrent bacterial vaginosis . These results were presented at the 2025 American College of Obstetricians and Gynecologists  Annual Clinical and Scientific Meeting. The study, involving 24 women, explored the efficacy of once-weekly SOLOSEC dosing. Findings indicate that the treatment effectively suppresses BV recurrence, potentially outperforming current CDC-recommended treatments. The simplicity of the once-weekly oral dose may enhance treatment adherence. While SOLOSEC is approved for BV treatment in women aged 12 and older, its use for recurrent BV is still investigational. The study's lead investigator, Dr. Chemen M. Neal, intends to submit the findings for publication in a peer-reviewed journal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL6xp3C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","EVFM"],"gpt_icon":0},{"id":"2542384920","title":"Evofem Biosciences CEO Saundra Pelletier Joins Aditxt Board of Directors to Propel Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2542384920","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542384920?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:15","pubTimestamp":1749471315,"startTime":"0","endTime":"0","summary":"Aditxt, Inc. has announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors. Ms. Pelletier brings extensive experience in the pharmaceutical industry, particularly in women's health, to Aditxt as the company aims to transition to a commercial stage and focus on areas impacting women's lives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire  on June 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL93M1q5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ADTX","BK4584","EVFM"],"gpt_icon":0},{"id":"2541955378","title":"IMAC Holdings Inc. Appoints Jason Lobel and Saundra Pelletier to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2541955378","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541955378?lang=en_us&edition=fundamental","pubTime":"2025-06-07 05:09","pubTimestamp":1749244172,"startTime":"0","endTime":"0","summary":"IMAC Holdings Inc. has announced the appointment of Jason Lobel and Saundra Pelletier to its Board of Directors as of June 2, 2025. Jason Lobel brings experience as a serial entrepreneur and CEO of GenomicMD, while Saundra Pelletier is recognized for her expertise in women's health and her leadership role at Evofem Biosciences, Inc. Their appointments are expected to enhance the company's strategic direction and leadership.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IMAC Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL8jP1Cb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4139","BK4007","EVFM","BACK","BK4185"],"gpt_icon":0},{"id":"2537482933","title":"Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2537482933","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537482933?lang=en_us&edition=fundamental","pubTime":"2025-05-21 20:59","pubTimestamp":1747832358,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC  in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL9xRfBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","EVFM","BK4007"],"gpt_icon":0},{"id":"2537123933","title":"Evofem Signs Solosec License Agreement for Middle East With Pharma 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2537123933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537123933?lang=en_us&edition=fundamental","pubTime":"2025-05-21 20:59","pubTimestamp":1747832344,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nTUAC5PGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2535957829","title":"Evofem Biosciences Q1 Sales $845.00K Down From $3.60M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535957829","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535957829?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:56","pubTimestamp":1747317418,"startTime":"0","endTime":"0","summary":"Evofem Biosciences (OTC:EVFM) reported $845.00 thousand in sales this quarter. This is a 76.55 percent decrease over sales of $3.60 million the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45438575/evofem-biosciences-q1-sales-845-00k-down-from-3-60m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM"],"gpt_icon":0},{"id":"2535593844","title":"Evofem Biosciences Reports Q1 2025 Net Income of $1M, Reversing $4.9M Loss YoY; EPS at $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2535593844","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535593844?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310360,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on May 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL7KvD8h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WINT","ADTX","EVFM"],"gpt_icon":0},{"id":"2535384482","title":"Evofem Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535384482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535384482?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUABCXFDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2535844846","title":"Evofem Biosciences Q1 Net Income USD 956 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2535844846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535844846?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nPLXE0AEBA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","EVFM","BK4007"],"gpt_icon":0},{"id":"2535784484","title":"Evofem Biosciences Q1 Operating Expenses USD 518 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2535784484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535784484?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nPLXE0AEBA:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2534516671","title":"Evofem Biosciences Expands Agreement with Pharma 1 Drug Store to Include New Product Packaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2534516671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534516671?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:08","pubTimestamp":1746734934,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has announced an amendment to its Development and Supply Agreement with Pharma 1 Drug Store L.L.C., a limited liability company based in the United Arab Emirates. The amendment, signed on May 3, 2025, introduces a new 3-applicator package size of the Licensed Product, in addition to the existing 12-applicator package. This strategic move aims to enhance product offerings and meet diverse consumer needs. The full details of the amendment are available in the company's Current Report on Form 8-K.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDLB3GJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","EVFM","BK4007"],"gpt_icon":0},{"id":"2528719078","title":"Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™","url":"https://stock-news.laohu8.com/highlight/detail?id=2528719078","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528719078?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:15","pubTimestamp":1744892100,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., April 17, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune, Inc. .Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Officer of Adimune, Inc.Event Details:Title: Aditxt Weekly UpdateDate: Friday, May 2, 2025Time: 11:30 a.m. ETLocation: Virtual Registration: Click here to register. ADI-100 is designed to work through precision immune reprogramming, downregulating pro-inflammatory cytokines while upregulating anti-inflammatory cytokine","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-charles-howe-mayo-clinic-121500791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0162691827.USD","LU2098885051.SGD","EVFM","BK4139","LU1303367103.USD","ADTX","BK4504","LU0072461881.USD","BK4584","BK4588","LU0211327993.USD","BK4082","BK4007","LU1267930490.SGD","BK4585","LU0006061336.USD","BAX","LU0211328371.USD","LU0310799852.SGD"],"gpt_icon":0},{"id":"2527948216","title":"Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527948216","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527948216?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:15","pubTimestamp":1744805700,"startTime":"0","endTime":"0","summary":"Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic Endometriosis Test, a potential non-invasive approach to surgical diagnosis for endometriosis. MOUNTAIN VIEW, Calif., April 16, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. , has received Institutional Review Board  approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic Endometriosis Test , a novel blood-based diagnostic designed to aid in the early detection of endometriosis.Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests. This diagnostic delay can lead to chronic pain, infertility and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-pearsanta-receives-irb-121500094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU1989771016.USD","ADTX","BK4588","LU1989772923.USD","BK4139","BK4584","BK4162","BK4585","EVFM","LU1291159041.SGD","LU1496350502.SGD","MET","LU1989772840.SGD"],"gpt_icon":0},{"id":"2527418139","title":"Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2527418139","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527418139?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"WARRINGTON, Pa., April  15, 2025  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage inno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3061660/0/en/Windtree-Therapeutics-Reports-Year-End-2024-Financial-Results-and-Provides-Key-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVFM","BK4007","BK4584","LENZ"],"gpt_icon":0},{"id":"2527549911","title":"Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549911","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549911?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"MIAMI, April 15, 2025  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-81-110000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","NQmain","NVA.AU","TQQQ","BK4139","QID","USJW.SI","ASBP","BK4017","NVAWW","NVA","BNZI","BK4162","BK4213","SEVCF","OMEX","BK4137","BK4583","BK4075","CLNN","URG","UURAF","BK4124",".IXIC","QLD","BK4077","MNQmain","TSYW.SI","BIXT","BK4584","BK4007","CIA","CUAUF","GOVX","USEG","BENF","XXII","SBC","BK4135","USAW.SI","NVIW.SI","ELRRF","BK4168","HGRAF","SQQQ","EVFM","BK4023","PSQH","BK4196","OPWEF"],"gpt_icon":1},{"id":"2527015710","title":"Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015710","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015710?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:15","pubTimestamp":1744632900,"startTime":"0","endTime":"0","summary":"Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune’s Lead Therapeutic Candidate for Autoimmune Diseases. The independent study, led by Dr. Sean Pittock and Dr. Charles Howe of the Mayo Clinic’s neuroimmunology team, confirmed that ADI-100 induces immune tolerance to glutamic acid decarboxylase —a key autoantigen implicated in multiple autoimmune conditions, including type 1 diabetes, stiff person syndrome, cerebellar ataxia, and autoimmune epilepsy.\"These results mark an important milestone not only for Adimune’s platform but also for Aditxt’s broader vision of transforming the way we approach autoimmune diseases,\" said Amro Albanna, co-founder and CEO of Aditxt. \"We believe that autoimmunity represents one of the most underserved and challenging areas of medicine. ADI-100’s potential ability to restore immune tolerance without broad immunosuppression is a meaningful step toward safer, more targeted treatments.\". Immune Modulation at the Cellul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-adimune-announces-positive-121500858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4504","LU0072461881.USD","BK4139","AAN","LU0162691827.USD","LU0310799852.SGD","BK4584","BK4588","LU2098885051.SGD","BK4082","BK4178","LU1303367103.USD","ADTX","LU0211328371.USD","LU0211327993.USD","LU1267930490.SGD","BK4007","BAX","EVFM","LU0006061336.USD"],"gpt_icon":0},{"id":"2526657426","title":"Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2526657426","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526657426?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:15","pubTimestamp":1744373700,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., April 11, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will provide key updates on recent events, including:. Aditxt’s recent notice from Nasdaq that it had regained compliance with Nasdaq’s minimum bid price requirement and is therefore in compliance with the Nasdaq Capital Market’s listing requirements. Event Details:Title: Aditxt Weekly UpdateDate: Friday, April 11, 2025Time: 11:30 a.m. ETLocation: Virtual Registration: Click here to register. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to \"Make Promising Innovations Possible Together.\" The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-weekly-highlight-recent-events-121500595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","BK4007","BK4588","IE00BKPKM429.USD","ADTX","NDAQ","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4112","LU2210150020.SGD","BK4139","EVFM","LU2095319765.USD",".IXIC","BK4585","IE00BGHQF748.EUR","BK4584"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVFM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691985600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVFM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVFM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVFM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVFM","date":"2022-08-05","current":-0.166395,"percent":0.950893,"low":-6.597859,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"high":-0.031142,"avg":-1.49806,"sd":1.032744,"marketCap":31769672},"quantilePoints":[{"date":"2020-07-10","current":-2.988359,"twenty":-2.741698,"median":-1.410607,"eighty":-0.977097,"marketCap":242388771},{"date":"2020-07-17","current":-2.813714,"twenty":-2.798191,"median":-1.413949,"eighty":-0.978316,"marketCap":228223193},{"date":"2020-07-24","current":-2.842822,"twenty":-2.813714,"median":-1.442913,"eighty":-0.981662,"marketCap":230584123},{"date":"2020-07-31","current":-2.901037,"twenty":-2.817595,"median":-1.451503,"eighty":-0.984607,"marketCap":235305982},{"date":"2020-08-07","current":-2.422033,"twenty":-2.817595,"median":-1.463115,"eighty":-0.986068,"marketCap":238151237},{"date":"2020-08-14","current":-2.587359,"twenty":-2.813714,"median":-1.465468,"eighty":-0.987517,"marketCap":254407295},{"date":"2020-08-21","current":-2.521229,"twenty":-2.813714,"median":-1.476662,"eighty":-0.988581,"marketCap":247904872},{"date":"2020-08-28","current":-2.587359,"twenty":-2.807893,"median":-1.489827,"eighty":-0.990273,"marketCap":254407295},{"date":"2020-09-04","current":-2.884947,"twenty":-2.813714,"median":-1.498338,"eighty":-0.994499,"marketCap":283668198},{"date":"2020-09-11","current":-1.735928,"twenty":-2.813714,"median":-1.501322,"eighty":-0.997697,"marketCap":170688600},{"date":"2020-09-18","current":-2.008717,"twenty":-2.809833,"median":-1.509563,"eighty":-0.999374,"marketCap":197511094},{"date":"2020-09-25","current":-1.84339,"twenty":-2.804012,"median":-1.510164,"eighty":-1.000561,"marketCap":181255037},{"date":"2020-10-02","current":-2.116179,"twenty":-2.804012,"median":-1.525046,"eighty":-1.001911,"marketCap":208077532},{"date":"2020-10-09","current":-2.397234,"twenty":-2.804012,"median":-1.542965,"eighty":-1.001911,"marketCap":235712829},{"date":"2020-10-16","current":-2.364169,"twenty":-2.800131,"median":-1.54827,"eighty":-1.001911,"marketCap":232461617},{"date":"2020-10-23","current":-2.083114,"twenty":-2.79431,"median":-1.561817,"eighty":-1.001911,"marketCap":204826320},{"date":"2020-10-30","current":-1.959119,"twenty":-2.790429,"median":-1.571494,"eighty":-1.002218,"marketCap":192634277},{"date":"2020-11-06","current":-2.025249,"twenty":-2.781758,"median":-1.588912,"eighty":-1.003413,"marketCap":199136700},{"date":"2020-11-13","current":-1.555597,"twenty":-2.774179,"median":-1.602459,"eighty":-1.004884,"marketCap":178003826},{"date":"2020-11-20","current":-1.655041,"twenty":-2.763731,"median":-1.588912,"eighty":-1.007151,"marketCap":189383066},{"date":"2020-11-27","current":-1.626629,"twenty":-2.753559,"median":-1.609695,"eighty":-1.009743,"marketCap":186131854},{"date":"2020-12-04","current":-1.576906,"twenty":-2.745522,"median":-1.591113,"eighty":-1.010116,"marketCap":180442234},{"date":"2020-12-11","current":-1.527184,"twenty":-2.743329,"median":-1.573429,"eighty":-1.011438,"marketCap":174752614},{"date":"2020-12-18","current":-1.47391,"twenty":-2.736486,"median":-1.569803,"eighty":-1.012602,"marketCap":168656593},{"date":"2020-12-24","current":-1.676351,"twenty":-2.729051,"median":-1.570648,"eighty":-1.013448,"marketCap":191821474},{"date":"2020-12-31","current":-1.726073,"twenty":-2.720643,"median":-1.573429,"eighty":-1.014445,"marketCap":197511094},{"date":"2021-01-08","current":-1.797105,"twenty":-2.718666,"median":-1.575364,"eighty":-1.014684,"marketCap":205639123},{"date":"2021-01-15","current":-1.889446,"twenty":-2.71669,"median":-1.596786,"eighty":-1.016196,"marketCap":216205560},{"date":"2021-01-22","current":-1.995994,"twenty":-2.705047,"median":-1.609695,"eighty":-1.017121,"marketCap":228397603},{"date":"2021-01-29","current":-1.882343,"twenty":-2.685112,"median":-1.620009,"eighty":-1.018306,"marketCap":215392757},{"date":"2021-02-05","current":-2.450598,"twenty":-2.681055,"median":-1.620116,"eighty":-1.018566,"marketCap":280416986},{"date":"2021-02-11","current":-2.507423,"twenty":-2.672813,"median":-1.632445,"eighty":-1.021168,"marketCap":286919409},{"date":"2021-02-19","current":-3.366908,"twenty":-2.71669,"median":-1.651829,"eighty":-1.024811,"marketCap":385268555},{"date":"2021-02-26","current":-2.848376,"twenty":-2.745246,"median":-1.655041,"eighty":-1.029338,"marketCap":325933946},{"date":"2021-03-05","current":-1.867672,"twenty":-2.747677,"median":-1.663725,"eighty":-1.032121,"marketCap":265786535},{"date":"2021-03-12","current":-1.676293,"twenty":-2.745246,"median":-1.660162,"eighty":-1.035221,"marketCap":238551624},{"date":"2021-03-19","current":-1.588682,"twenty":-2.743329,"median":-1.655041,"eighty":-1.038349,"marketCap":226083769},{"date":"2021-03-26","current":-1.204757,"twenty":-2.736696,"median":-1.653841,"eighty":-1.038718,"marketCap":171447831},{"date":"2021-04-01","current":-1.233,"twenty":-2.727622,"median":-1.645078,"eighty":-1.04011,"marketCap":175467057},{"date":"2021-04-09","current":-1.240046,"twenty":-2.726572,"median":-1.626629,"eighty":-1.040946,"marketCap":176469726},{"date":"2021-04-16","current":-1.099132,"twenty":-2.71669,"median":-1.619767,"eighty":-1.04998,"marketCap":156416348},{"date":"2021-04-23","current":-1.070949,"twenty":-2.71669,"median":-1.605319,"eighty":-1.04998,"marketCap":152405672},{"date":"2021-04-30","current":-1.055056,"twenty":-2.697285,"median":-1.589897,"eighty":-1.040946,"marketCap":150143944},{"date":"2021-05-07","current":-0.881622,"twenty":-2.676997,"median":-1.577001,"eighty":-1.04011,"marketCap":125462747},{"date":"2021-05-14","current":-0.740987,"twenty":-2.670023,"median":-1.573429,"eighty":-1.033139,"marketCap":125459522},{"date":"2021-05-21","current":-0.773593,"twenty":-2.664959,"median":-1.570648,"eighty":-1.021948,"marketCap":130980172},{"date":"2021-05-28","current":-0.728459,"twenty":-2.655531,"median":-1.567623,"eighty":-1.014684,"marketCap":123338388},{"date":"2021-06-04","current":-0.795167,"twenty":-2.64853,"median":-1.5627,"eighty":-1.010667,"marketCap":134632945},{"date":"2021-06-11","current":-0.94781,"twenty":-2.640264,"median":-1.559356,"eighty":-1.003779,"marketCap":160477457},{"date":"2021-06-18","current":-1.047104,"twenty":-2.607198,"median":-1.555597,"eighty":-1.003779,"marketCap":177289381},{"date":"2021-06-25","current":-1.083211,"twenty":-2.587359,"median":-1.554323,"eighty":-1.003779,"marketCap":183402808},{"date":"2021-07-02","current":-0.992944,"twenty":-2.577755,"median":-1.54827,"eighty":-1.003779,"marketCap":168119241},{"date":"2021-07-08","current":-0.868645,"twenty":-2.571247,"median":-1.543397,"eighty":-1.001923,"marketCap":147073769},{"date":"2021-07-16","current":-0.830462,"twenty":-2.570827,"median":-1.534287,"eighty":-1.001911,"marketCap":140608820},{"date":"2021-07-23","current":-0.837683,"twenty":-2.569976,"median":-1.527184,"eighty":-0.997201,"marketCap":141831505},{"date":"2021-07-30","current":-0.79598,"twenty":-2.566348,"median":-1.527184,"eighty":-0.989357,"marketCap":134770497},{"date":"2021-08-05","current":-0.721238,"twenty":-2.565456,"median":-1.525046,"eighty":-0.985216,"marketCap":122115703},{"date":"2021-08-13","current":-0.777143,"twenty":-2.558807,"median":-1.510765,"eighty":-0.977482,"marketCap":116628902},{"date":"2021-08-20","current":-0.693957,"twenty":-2.535025,"median":-1.509563,"eighty":-0.970593,"marketCap":104144873},{"date":"2021-08-26","current":-0.857569,"twenty":-2.527842,"median":-1.509563,"eighty":-0.967886,"marketCap":128698851},{"date":"2021-09-03","current":-0.906177,"twenty":-2.522882,"median":-1.501822,"eighty":-0.966863,"marketCap":135993649},{"date":"2021-09-10","current":-0.876599,"twenty":-2.521229,"median":-1.500822,"eighty":-0.963107,"marketCap":131554687},{"date":"2021-09-17","current":-0.840815,"twenty":-2.51909,"median":-1.498725,"eighty":-0.951877,"marketCap":126184474},{"date":"2021-09-24","current":-0.807824,"twenty":-2.515298,"median":-1.49021,"eighty":-0.949203,"marketCap":121233324},{"date":"2021-10-01","current":-0.76387,"twenty":-2.512963,"median":-1.485821,"eighty":-0.94602,"marketCap":114636965},{"date":"2021-10-06","current":-0.761491,"twenty":-2.512963,"median":-1.483516,"eighty":-0.944019,"marketCap":114279986},{"date":"2021-10-15","current":-0.741324,"twenty":-2.509639,"median":-1.470856,"eighty":-0.935834,"marketCap":111253421},{"date":"2021-10-22","current":-0.733671,"twenty":-2.500827,"median":-1.466227,"eighty":-0.933578,"marketCap":110104878},{"date":"2021-10-29","current":-0.716089,"twenty":-2.49643,"median":-1.463115,"eighty":-0.930358,"marketCap":107466334},{"date":"2021-11-05","current":-0.739117,"twenty":-2.49147,"median":-1.455373,"eighty":-0.92436,"marketCap":110922261},{"date":"2021-11-12","current":-0.728355,"twenty":-2.482486,"median":-1.447004,"eighty":-0.920137,"marketCap":109307125},{"date":"2021-11-19","current":-0.386369,"twenty":-2.475346,"median":-1.419951,"eighty":-0.911743,"marketCap":75046683},{"date":"2021-11-26","current":-0.368646,"twenty":-2.470234,"median":-1.413372,"eighty":-0.910828,"marketCap":71604324},{"date":"2021-12-03","current":-0.345128,"twenty":-2.465921,"median":-1.409387,"eighty":-0.907248,"marketCap":67036265},{"date":"2021-12-10","current":-0.403167,"twenty":-2.463597,"median":-1.40309,"eighty":-0.905738,"marketCap":78309582},{"date":"2021-12-17","current":-0.313295,"twenty":-2.456306,"median":-1.389572,"eighty":-0.903748,"marketCap":60853071},{"date":"2021-12-23","current":-0.34748,"twenty":-2.450022,"median":-1.381831,"eighty":-0.902029,"marketCap":67493071},{"date":"2021-12-31","current":-0.319174,"twenty":-2.445888,"median":-1.378837,"eighty":-0.897011,"marketCap":61995086},{"date":"2022-01-07","current":-0.336561,"twenty":-2.438566,"median":-1.374379,"eighty":-0.890009,"marketCap":65372187},{"date":"2022-01-14","current":-0.330546,"twenty":-2.435259,"median":-1.374379,"eighty":-0.887406,"marketCap":64203917},{"date":"2022-01-21","current":-0.359744,"twenty":-2.422033,"median":-1.373004,"eighty":-0.88461,"marketCap":69875182},{"date":"2022-01-28","current":-0.344601,"twenty":-2.410537,"median":-1.364205,"eighty":-0.879684,"marketCap":66933925},{"date":"2022-02-04","current":-0.364261,"twenty":-2.408407,"median":-1.361316,"eighty":-0.876997,"marketCap":70752685},{"date":"2022-02-11","current":-0.35121,"twenty":-2.407979,"median":-1.360635,"eighty":-0.873952,"marketCap":68217678},{"date":"2022-02-18","current":-0.3999,"twenty":-2.4055,"median":-1.357152,"eighty":-0.868989,"marketCap":77675059},{"date":"2022-02-25","current":-0.401239,"twenty":-2.4055,"median":-1.354255,"eighty":-0.866236,"marketCap":77935059},{"date":"2022-03-04","current":-0.423267,"twenty":-2.4055,"median":-1.3492,"eighty":-0.857291,"marketCap":82213674},{"date":"2022-03-11","current":-0.320697,"twenty":-2.398887,"median":-1.346995,"eighty":-0.853506,"marketCap":65804496},{"date":"2022-03-18","current":-0.329119,"twenty":-2.397234,"median":-1.344895,"eighty":-0.847851,"marketCap":67532661},{"date":"2022-03-25","current":-0.325812,"twenty":-2.388918,"median":-1.342548,"eighty":-0.840765,"marketCap":66854009},{"date":"2022-04-01","current":-0.301935,"twenty":-2.383963,"median":-1.338645,"eighty":-0.83736,"marketCap":61954723},{"date":"2022-04-08","current":-0.227428,"twenty":-2.374597,"median":-1.333793,"eighty":-0.827311,"marketCap":46666484},{"date":"2022-04-14","current":-0.208602,"twenty":-2.367475,"median":-1.327882,"eighty":-0.818669,"marketCap":42803424},{"date":"2022-04-22","current":-0.177964,"twenty":-2.354249,"median":-1.324122,"eighty":-0.811433,"marketCap":36516842},{"date":"2022-04-29","current":-0.158072,"twenty":-2.337716,"median":-1.320898,"eighty":-0.80387,"marketCap":32435119},{"date":"2022-05-06","current":-0.09804,"twenty":-2.330036,"median":-1.319106,"eighty":-0.796197,"marketCap":20117060},{"date":"2022-05-13","current":-0.079302,"twenty":-2.325012,"median":-1.317041,"eighty":-0.793147,"marketCap":15141105},{"date":"2022-05-20","current":-0.073245,"twenty":-2.319979,"median":-1.316551,"eighty":-0.779563,"marketCap":13984579},{"date":"2022-05-27","current":-0.067867,"twenty":-2.309914,"median":-1.316029,"eighty":-0.776301,"marketCap":12957856},{"date":"2022-06-03","current":-0.067242,"twenty":-2.299849,"median":-1.310904,"eighty":-0.774424,"marketCap":12838360},{"date":"2022-06-10","current":-0.072366,"twenty":-2.291941,"median":-1.307915,"eighty":-0.769174,"marketCap":13816734},{"date":"2022-06-17","current":-0.056191,"twenty":-2.289784,"median":-1.302231,"eighty":-0.761429,"marketCap":10728507},{"date":"2022-06-24","current":-0.062195,"twenty":-2.288346,"median":-1.300568,"eighty":-0.758763,"marketCap":11874923},{"date":"2022-07-01","current":-0.221009,"twenty":-2.282377,"median":-1.299044,"eighty":-0.754436,"marketCap":42197054},{"date":"2022-07-08","current":-0.244479,"twenty":-2.281505,"median":-1.297414,"eighty":-0.747488,"marketCap":46678157},{"date":"2022-07-15","current":-0.209401,"twenty":-2.275405,"median":-1.296606,"eighty":-0.743702,"marketCap":39980638},{"date":"2022-07-22","current":-0.185295,"twenty":-2.264621,"median":-1.294665,"eighty":-0.739566,"marketCap":35378254},{"date":"2022-07-29","current":-0.137119,"twenty":-2.253837,"median":-1.292774,"eighty":-0.734705,"marketCap":26179907},{"date":"2022-08-05","current":-0.166395,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"marketCap":31769672}],"updateTime":1751836727188}}}